{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:36:41Z","timestamp":1790735801122,"version":"4.1.0"},"reference-count":282,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2023,4,7]],"date-time":"2023-04-07T00:00:00Z","timestamp":1680825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>CRISPR-Cas technology has rapidly changed life science research and human medicine. The ability to add, remove, or edit human DNA sequences has transformative potential for treating congenital and acquired human diseases. The timely maturation of the cell and gene therapy ecosystem and its seamless integration with CRISPR-Cas technologies has enabled the development of therapies that could potentially cure not only monogenic diseases such as sickle cell anemia and muscular dystrophy, but also complex heterogenous diseases such as cancer and diabetes. Here, we review the current landscape of clinical trials involving the use of various CRISPR-Cas systems as therapeutics for human diseases, discuss challenges, and explore new CRISPR-Cas-based tools such as base editing, prime editing, CRISPR-based transcriptional regulation, CRISPR-based epigenome editing, and RNA editing, each promising new functionality and broadening therapeutic potential. Finally, we discuss how the CRISPR-Cas system is being used to understand the biology of human diseases through the generation of large animal disease models used for preclinical testing of emerging therapeutics.<\/jats:p>","DOI":"10.3390\/cells12081103","type":"journal-article","created":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T03:15:57Z","timestamp":1681096557000},"page":"1103","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["CRISPR-Cas System: The Current and Emerging Translational Landscape"],"prefix":"10.3390","volume":"12","author":[{"given":"Narendranath","family":"Bhokisham","sequence":"first","affiliation":[{"name":"Corporate Research Material Labs, 3M Center, 3M Company, Maplewood, MN 55144, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan","family":"Laudermilch","sequence":"additional","affiliation":[{"name":"Corporate Research Material Labs, 3M Center, 3M Company, Maplewood, MN 55144, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5000-1990","authenticated-orcid":false,"given":"Lindsay L.","family":"Traeger","sequence":"additional","affiliation":[{"name":"Corporate Research Material Labs, 3M Center, 3M Company, Maplewood, MN 55144, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tonya D.","family":"Bonilla","sequence":"additional","affiliation":[{"name":"Corporate Research Material Labs, 3M Center, 3M Company, Maplewood, MN 55144, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes","family":"Ruiz-Estevez","sequence":"additional","affiliation":[{"name":"Corporate Research Material Labs, 3M Center, 3M Company, Maplewood, MN 55144, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan R.","family":"Becker","sequence":"additional","affiliation":[{"name":"Corporate Research Material Labs, 3M Center, 3M Company, Maplewood, MN 55144, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,4,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1126\/science.1225829","article-title":"A Programmable Dual-RNA\u2013Guided DNA Endonuclease in Adaptive Bacterial Immunity","volume":"337","author":"Jinek","year":"2012","journal-title":"Science"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/nrm1202","article-title":"Mechanism and Regulation of Human Non-Homologous DNA End-Joining","volume":"4","author":"Lieber","year":"2003","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1038\/s41556-019-0425-z","article-title":"Advances in Genome Editing through Control of DNA Repair Pathways","volume":"21","author":"Yeh","year":"2019","journal-title":"Nat. Cell Biol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.tig.2021.02.008","article-title":"DNA Repair Pathway Choices in CRISPR-Cas9-Mediated Genome Editing","volume":"37","author":"Xue","year":"2021","journal-title":"Trends Genet."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.cell.2015.12.035","article-title":"Biology and Applications of CRISPR Systems: Harnessing Nature\u2019s Toolbox for Genome Engineering","volume":"164","author":"Wright","year":"2016","journal-title":"Cell"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1258096","DOI":"10.1126\/science.1258096","article-title":"The New Frontier of Genome Engineering with CRISPR-Cas9","volume":"346","author":"Doudna","year":"2014","journal-title":"Science"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nrd.2016.238","article-title":"Cornerstones of CRISPR\u2013Cas in Drug Discovery and Therapy","volume":"16","author":"Fellmann","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/s41477-019-0461-5","article-title":"The Emerging and Uncultivated Potential of CRISPR Technology in Plant Science","volume":"5","author":"Zhang","year":"2019","journal-title":"Nat. Plants"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.tibtech.2017.07.007","article-title":"Advances in Industrial Biotechnology Using CRISPR-Cas Systems","volume":"36","author":"Donohoue","year":"2018","journal-title":"Trends Biotechnol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e264","DOI":"10.1038\/mtna.2015.37","article-title":"Off-Target Effects in CRISPR\/Cas9-Mediated Genome Engineering","volume":"4","author":"Zhang","year":"2015","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/s41587-020-0561-9","article-title":"Genome Editing with CRISPR-Cas Nucleases, Base Editors, Transposases and Prime Editors","volume":"38","author":"Anzalone","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.cell.2013.02.022","article-title":"Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression","volume":"152","author":"Qi","year":"2013","journal-title":"Cell"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/nmeth.2600","article-title":"RNA-Guided Gene Activation by CRISPR-Cas9\u2013Based Transcription Factors","volume":"10","author":"Kocak","year":"2013","journal-title":"Nat. Methods"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1021\/acschembio.7b00657","article-title":"CRISPRi and CRISPRa Screens in Mammalian Cells for Precision Biology and Medicine","volume":"13","author":"Kampmann","year":"2018","journal-title":"ACS Chem. Biol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1126\/science.aaq0180","article-title":"RNA Editing with CRISPR-Cas13","volume":"358","author":"Cox","year":"2017","journal-title":"Science"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/s41586-021-03886-5","article-title":"Programmable RNA Targeting with the Single-Protein CRISPR Effector Cas7-11","volume":"597","author":"Krajeski","year":"2021","journal-title":"Nature"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/bs.pmbts.2017.07.010","article-title":"Chapter Six\u2014CRISPR in Animals and Animal Models","volume":"Volume 152","year":"2017","journal-title":"Progress in Molecular Biology and Translational Science"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13024-015-0031-x","article-title":"CRISPR\/Cas9: A Powerful Genetic Engineering Tool for Establishing Large Animal Models of Neurodegenerative Diseases","volume":"10","author":"Tu","year":"2015","journal-title":"Mol. Neurodegener."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Lim, K.R.Q., Nguyen, Q., Dzierlega, K., Huang, Y., and Yokota, T. (2020). CRISPR-Generated Animal Models of Duchenne Muscular Dystrophy. Genes, 11.","DOI":"10.20944\/preprints202003.0048.v1"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/mt.2016.10","article-title":"Genome-Editing Technologies for Gene and Cell Therapy","volume":"24","author":"Maeder","year":"2016","journal-title":"Mol. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12943-022-01559-z","article-title":"Engineering the Next-Generation of CAR T-Cells with CRISPR-Cas9 Gene Editing","volume":"21","author":"Dimitri","year":"2022","journal-title":"Mol. Cancer"},{"key":"ref_22","unstructured":"(2022, December 15). US National Library of Medicine, ClinicalTrials.gov, Available online: https:\/\/ClinicalTrials.Gov\/show\/NCT05397184."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00428-018-2484-0","article-title":"Adoptive Cellular Therapies: The Current Landscape","volume":"474","author":"Rohaan","year":"2019","journal-title":"Virchows Arch."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1126\/science.aaa4967","article-title":"Adoptive Cell Transfer as Personalized Immunotherapy for Human Cancer","volume":"348","author":"Rosenberg","year":"2015","journal-title":"Science"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T Cell Immunotherapy for Human Cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"ref_26","unstructured":"(2022, December 15). US Food and Drug Administratio, Available online: https:\/\/www.fda.gov\/Vaccines-Blood-Biologics\/Cellular-Gene-Therapy-Products\/Approved-Cellular-and-Gene-Therapy-Products."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"835762","DOI":"10.3389\/fimmu.2022.835762","article-title":"Cancer Therapy with TCR-Engineered T Cells: Current Strategies, Challenges, and Prospects","volume":"13","author":"Shafer","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/imr.12132","article-title":"Exploiting the Curative Potential of Adoptive T-Cell Therapy for Cancer","volume":"257","author":"Hinrichs","year":"2014","journal-title":"Immunol. Rev."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1182\/blood-2021-146393","article-title":"Real-World Outcomes for Pediatric and Young Adult Patients with Relapsed or Refractory (R\/R) B-Cell Acute Lymphoblastic Leukemia (ALL) Treated with Tisagenlecleucel: Update from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry","volume":"138","author":"John","year":"2021","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1182\/blood-2021-148078","article-title":"Long-Term (\u22654 Year and \u22655 Year) Overall Survival (OS) By 12- and 24-Month Event-Free Survival (EFS): An Updated Analysis of ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Refractory Large B-Cell Lymphoma (LBCL)","volume":"138","author":"Jacobson","year":"2021","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","article-title":"Tumor Antigen Escape from CAR T-Cell Therapy","volume":"8","author":"Majzner","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1146\/annurev-med-062315-120245","article-title":"CAR T Cell Therapy for Solid Tumors","volume":"68","author":"Newick","year":"2017","journal-title":"Annu. Rev. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1038\/s41416-021-01353-6","article-title":"Promises and Challenges of Adoptive T-Cell Therapies for Solid Tumours","volume":"124","author":"Morotti","year":"2021","journal-title":"Br. J. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"103941","DOI":"10.1016\/j.ebiom.2022.103941","article-title":"Improving CAR-T Immunotherapy: Overcoming the Challenges of T Cell Exhaustion","volume":"77","author":"Gumber","year":"2022","journal-title":"eBioMedicine"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13045-019-0801-y","article-title":"Targeting T Cell Malignancies Using CAR-Based Immunotherapy: Challenges and Potential Solutions","volume":"12","author":"Fleischer","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T Cell Therapy: Current Limitations and Potential Strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41568-020-00323-z","article-title":"Recent Advances and Discoveries in the Mechanisms and Functions of CAR T Cells","volume":"21","author":"Larson","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.it.2015.02.008","article-title":"Overcoming T Cell Exhaustion in Infection and Cancer","volume":"36","author":"Pauken","year":"2015","journal-title":"Trends Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMra1514296","article-title":"Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway","volume":"375","author":"Boussiotis","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2016-09-738245","article-title":"PD-1 Blockade Modulates Chimeric Antigen Receptor (CAR)\u2013Modified T Cells: Refueling the CAR","volume":"129","author":"Chong","year":"2017","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1186\/s40425-019-0806-7","article-title":"CRISPR-Cas9 Disruption of PD-1 Enhances Activity of Universal EGFRvIII CAR T Cells in a Preclinical Model of Human Glioblastoma","volume":"7","author":"Choi","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/s41598-017-00462-8","article-title":"CRISPR\/Cas9-Mediated PD-1 Disruption Enhances Anti-Tumor Efficacy of Human Chimeric Antigen Receptor T Cells","volume":"7","author":"Rupp","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_43","unstructured":"(2022, December 15). US National Library of Medicine, ClinicalTrials.gov, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT04417764."},{"key":"ref_44","unstructured":"(2022, December 15). US National Library of Medicine, ClinicalTrials.gov, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT03081715."},{"key":"ref_45","unstructured":"(2022, December 15). US National Library of Medicine, ClinicalTrials.gov, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT02793856."},{"key":"ref_46","unstructured":"(2022, December 15). US National Library of Medicine, ClinicalTrials.gov, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT03044743."},{"key":"ref_47","unstructured":"(2022, December 15). US National Library of Medicine, ClinicalTrials.gov, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT03545815."},{"key":"ref_48","unstructured":"(2022, December 15). US National Library of Medicine, ClinicalTrials.gov, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT03747965."},{"key":"ref_49","unstructured":"(2022, December 15). US National Library of Medicine, ClinicalTrials.gov, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT03399448."},{"key":"ref_50","unstructured":"(2022, December 15). US National Library of Medicine, ClinicalTrials.gov, Available online: https:\/\/Clinicaltrials.gov\/show\/NCT04637763."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"eaba7365","DOI":"10.1126\/science.aba7365","article-title":"CRISPR-Engineered T Cells in Patients with Refractory Cancer","volume":"367","author":"Stadtmauer","year":"2020","journal-title":"Science"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/s41591-020-0840-5","article-title":"Safety and Feasibility of CRISPR-Edited T Cells in Patients with Refractory Non-Small-Cell Lung Cancer","volume":"26","author":"Lu","year":"2020","journal-title":"Nat. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1038\/s41423-021-00749-x","article-title":"Phase I Study of CAR-T Cells with PD-1 and TCR Disruption in Mesothelin-Positive Solid Tumors","volume":"18","author":"Wang","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/nm.3910","article-title":"NY-ESO-1\u2013Specific TCR\u2013Engineered T Cells Mediate Sustained Antigen-Specific Antitumor Effects in Myeloma","volume":"21","author":"Rapoport","year":"2015","journal-title":"Nat. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1158\/1078-0432.CCR-14-2708","article-title":"A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1\u2013Reactive T-Cell Receptor: Long-Term Follow-up and Correlates with Response","volume":"21","author":"Robbins","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1158\/2159-8290.CD-17-1417","article-title":"Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 C259T Cells in Synovial Sarcoma","volume":"8","author":"Melchiori","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1158\/2159-8290.CD-21-0407","article-title":"A Phase I Trial of Regional Mesothelin-Targeted CAR T-Cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti\u2013PD-1 Agent Pembrolizumab","volume":"11","author":"Adusumilli","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.medj.2022.07.008","article-title":"Internal Checkpoint Regulates T Cell Neoantigen Reactivity and Susceptibility to PD1 Blockade","volume":"3","author":"Palmer","year":"2022","journal-title":"Med"},{"key":"ref_59","unstructured":"(2022, December 15). US National Library of Medicine, ClinicalTrials.gov, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT05566223."},{"key":"ref_60","unstructured":"(2022, December 15). US National Library of Medicine, ClinicalTrials.gov, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT04426669."},{"key":"ref_61","unstructured":"(2022, December 15). US National Library of Medicine, ClinicalTrials.gov, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT04767308."},{"key":"ref_62","unstructured":"(2022, December 15). US National Library of Medicine, ClinicalTrials.gov, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT04037566."},{"key":"ref_63","unstructured":"(2022, December 15). US National Library of Medicine, ClinicalTrials.gov, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT04976218."},{"key":"ref_64","unstructured":"(2022, December 15). US National Library of Medicine, ClinicalTrials.gov, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT05066165."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1002\/ajh.25399","article-title":"Allogeneic CAR T Cell Therapies for Leukemia","volume":"94","author":"Qasim","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"eabq3010","DOI":"10.1126\/scitranslmed.abq3010","article-title":"Phase 1 Clinical Trial of CRISPR-Engineered CAR19 Universal T Cells for Treatment of Children with Refractory B Cell Leukemia","volume":"14","author":"Ottaviano","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"\u2018Off-the-Shelf\u2019 Allogeneic CAR T Cells: Development and Challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_68","unstructured":"(2022, December 15). US National Library of Medicine, ClinicalTrials.gov, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT03166878."},{"key":"ref_69","unstructured":"(2022, December 15). US National Library of Medicine, ClinicalTrials.gov, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT03398967."},{"key":"ref_70","unstructured":"(2022, December 15). US National Library of Medicine, ClinicalTrials.gov, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT04557436."},{"key":"ref_71","unstructured":"(2022, December 15). US National Library of Medicine, ClinicalTrials.gov, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT04502446."},{"key":"ref_72","unstructured":"(2022, December 15). US National Library of Medicine, ClinicalTrials.gov, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT04438083."},{"key":"ref_73","unstructured":"(2022, December 15). US National Library of Medicine, ClinicalTrials.gov, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT04035434."},{"key":"ref_74","unstructured":"(2022, December 15). US National Library of Medicine, ClinicalTrials.gov, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT04244656."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC Locus with CRISPR\/Cas9 Enhances Tumour Rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"9457","DOI":"10.1182\/blood-2022-168128","article-title":"A First-in-Human Phase 1, Multicenter, Open-Label Study of CB-010, a Next-Generation CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy with a PD-1 Knockout, in Patients with Relapsed\/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER Study)","volume":"140","author":"Nastoupil","year":"2022","journal-title":"Blood"},{"key":"ref_77","unstructured":"(2022, December 15). US National Library of Medicine, ClinicalTrials.gov, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT05309733."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1089\/hum.2014.2525","article-title":"Vector Integration and Tumorigenesis","volume":"25","author":"Deichmann","year":"2014","journal-title":"Hum. Gene Ther."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1016\/j.ymthe.2021.07.001","article-title":"The Rational Development of CD5-Targeting Biepitopic CARs with Fully Human Heavy-Chain-Only Antigen Recognition Domains","volume":"29","author":"Dai","year":"2021","journal-title":"Mol. Ther."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/01.HS9.0000843940.96598.e2","article-title":"S262: The Cobalt-Lym Study of Ctx130: A Phase 1 Dose Escalation Study of Cd70-Targeted Allogeneic Crispr-Cas9\u2013Engineered Car T Cells in Patients with Relapsed\/Refractory (R\/R) T-Cell Malignancies","volume":"6","author":"Iyer","year":"2022","journal-title":"HemaSphere"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ccell.2020.08.001","article-title":"Hematopoietic Progenitor Kinase1 (HPK1) Mediates T Cell Dysfunction and Is a Druggable Target for T Cell-Based Immunotherapies","volume":"38","author":"Si","year":"2020","journal-title":"Cancer Cell"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"7041","DOI":"10.1200\/JCO.2022.40.16_suppl.7041","article-title":"Decreasing HPK1 Expression in CD19 CAR-T Cells: A Novel Strategy to Overcome Challenges of Cell Therapy for Adult (r\/r) B-ALL","volume":"40","author":"Zhang","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1182\/blood-2021-153775","article-title":"Clinical-Scale Production and Characterization of Ntla-5001\u2014A Novel Approach to Manufacturing CRISPR\/Cas9 Engineered T Cell Therapies","volume":"138","author":"Cossette","year":"2021","journal-title":"Blood"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"eaaj2013","DOI":"10.1126\/scitranslmed.aaj2013","article-title":"Molecular Remission of Infant B-ALL after Infusion of Universal TALEN Gene-Edited CAR T Cells","volume":"9","author":"Qasim","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_85","unstructured":"(2022, December 15). US National Library of Medicine, ClinicalTrials.gov, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT03655678."},{"key":"ref_86","unstructured":"(2022, December 15). US National Library of Medicine, ClinicalTrials.gov, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT05477563."},{"key":"ref_87","unstructured":"(2022, December 15). US National Library of Medicine, ClinicalTrials.gov, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT03745287."},{"key":"ref_88","unstructured":"(2022, December 15). US National Library of Medicine, ClinicalTrials.gov, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT05356195."},{"key":"ref_89","unstructured":"(2022, December 15). US National Library of Medicine, ClinicalTrials.gov, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT05329649."},{"key":"ref_90","unstructured":"(2022, December 15). US National Library of Medicine, ClinicalTrials.gov, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT04208529."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.ejphar.2019.04.042","article-title":"Targeted Deletion of BCL11A Gene by CRISPR-Cas9 System for Fetal Hemoglobin Reactivation: A Promising Approach for Gene Therapy of Beta Thalassemia Disease","volume":"854","author":"Khosravi","year":"2019","journal-title":"Eur. J. Pharmacol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1056\/NEJMoa2031054","article-title":"CRISPR-Cas9 Gene Editing for Sickle Cell Disease and \u03b2-Thalassemia","volume":"384","author":"Frangoul","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1182\/blood-2022-162353","article-title":"Efficacy and Safety of a Single Dose of Exagamglogene Autotemcel for Severe Sickle Cell Disease","volume":"140","author":"Frangoul","year":"2022","journal-title":"Blood"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"4899","DOI":"10.1182\/blood-2022-166881","article-title":"Efficacy and Safety of a Single Dose of Exagamglogene Autotemcel for Transfusion-Dependent \u03b2-Thalassemia","volume":"140","author":"Locatelli","year":"2022","journal-title":"Blood"},{"key":"ref_95","unstructured":"(2022, December 15). US National Library of Medicine, ClinicalTrials.gov, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT04925206."},{"key":"ref_96","unstructured":"(2022, December 15). US National Library of Medicine, ClinicalTrials.gov, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT04390971."},{"key":"ref_97","unstructured":"(2022, December 15). US National Library of Medicine, ClinicalTrials.gov, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT05577312."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"10652","DOI":"10.1182\/blood-2022-166365","article-title":"Preliminary Safety and Efficacy Results of EDI001: An Investigator Initiated Trial on CRISPR\/Cas9-Modified Autologous CD34+ Hematopoietic Stem and Progenitor Cells for Patients with Transfusion Dependent \u03b2-Thalassemia","volume":"140","author":"Shi","year":"2022","journal-title":"Blood"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1038\/s41591-022-01906-z","article-title":"CRISPR-Cas9-Mediated Gene Editing of the BCL11A Enhancer for Pediatric \u03920\/\u03920 Transfusion-Dependent \u03b2-Thalassemia","volume":"28","author":"Fu","year":"2022","journal-title":"Nat. Med."},{"key":"ref_100","unstructured":"(2022, December 15). US National Library of Medicine, ClinicalTrials.gov, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT04819841."},{"key":"ref_101","unstructured":"(2022, December 15). US National Library of Medicine, ClinicalTrials.gov, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT04774536."},{"key":"ref_102","unstructured":"(2022, December 15). US National Library of Medicine, ClinicalTrials.gov, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT03728322."},{"key":"ref_103","unstructured":"(2022, December 15). US National Library of Medicine, ClinicalTrials.gov, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT04211480."},{"key":"ref_104","unstructured":"(2022, December 15). US National Library of Medicine, ClinicalTrials.gov, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT05444894."},{"key":"ref_105","unstructured":"(2022, December 15). US National Library of Medicine, ClinicalTrials.gov, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT04853576."},{"key":"ref_106","unstructured":"(2022, December 15). US National Library of Medicine, ClinicalTrials.gov, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT05210530."},{"key":"ref_107","unstructured":"(2022, December 15). US National Library of Medicine, ClinicalTrials.gov, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT03872479."},{"key":"ref_108","unstructured":"(2022, December 15). US National Library of Medicine, ClinicalTrials.gov, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT05120830."},{"key":"ref_109","unstructured":"(2022, December 15). US National Library of Medicine, ClinicalTrials.gov, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT05514249."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"4636","DOI":"10.1182\/blood-2019-130256","article-title":"EDIT-301: An Experimental Autologous Cell Therapy Comprising Cas12a-RNP Modified MPB-CD34+ Cells for the Potential Treatment of SCD","volume":"134","author":"Heath","year":"2019","journal-title":"Blood"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1182\/blood-2021-149956","article-title":"Preclinical Development of EDIT301, an Autologous Cell Therapy Comprising AsCas12a-RNP Modified Mobilized Peripheral Blood-CD34+ Cells for the Potential Treatment of Transfusion Dependent Beta Thalassemia","volume":"138","author":"Sousa","year":"2021","journal-title":"Blood"},{"key":"ref_112","unstructured":"(2022, December 06). Editas Medicine. Editas Medicine Announces Positive Safety and Efficacy Data from the First Two Patients Treated in the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease. Press Release. Available online: https:\/\/ir.editasmedicine.com\/news-releases\/news-release-details\/editas-medicine-announces-positive-safety-and-efficacy-data."},{"key":"ref_113","unstructured":"Kanter, J., Di Persio, J.F., Leavey, P., Shyr, D.C., Thompson, A.A., Porteus, M.H., Intondi, A., Lahiri, P., Dever, D.P., and Petrusich, A. (2021). 2021 ASH Annual Meeting and Exposition, Elsevier."},{"key":"ref_114","unstructured":"(2022, August 11). Graphite Bio. Graphite Bio Doses First Patient with Investigational Gene Editing Therapy GPH101 for Sickle Cell Disease [Press Release]. Available online: https:\/\/ir.graphitebio.com\/press-releases\/detail\/76\/graphite-bio-doses-first-patient-with-investigational-gene."},{"key":"ref_115","unstructured":"(2023, January 05). Graphite Bio. Graphite Bio Announces Voluntary Pause of Phase 1\/2 CEDAR Study of Nulabeglogene Autogedtemcel (Nula-Cel) for Sickle Cell Disease. [Press Release]. Available online: https:\/\/ir.graphitebio.com\/press-releases\/detail\/84\/graphite-bio-announces-voluntary-pause-of-phase-12-cedar."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/j.stem.2021.10.003","article-title":"Implanted Pluripotent Stem-Cell-Derived Pancreatic Endoderm Cells Secrete Glucose-Responsive C-Peptide in Patients with Type 1 Diabetes","volume":"28","author":"Ramzy","year":"2021","journal-title":"Cell Stem Cell"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"100466","DOI":"10.1016\/j.xcrm.2021.100466","article-title":"Insulin Expression and C-Peptide in Type 1 Diabetes Subjects Implanted with Stem Cell-Derived Pancreatic Endoderm Cells in an Encapsulation Device","volume":"2","author":"Shapiro","year":"2021","journal-title":"Cell Rep. Med."},{"key":"ref_118","unstructured":"(2023, February 02). CRISPR Theraputics. CRISPR Therapeutics and ViaCyte, Inc. Announce First Patient Dosed in Phase 1 Clinical Trial of Novel Gene-Edited Cell Replacement Therapy for Treatment of Type 1 Diabetes (T1D). [Press Release]. Available online: https:\/\/crisprtx.com\/about-us\/press-releases-and-presentations\/crispr-therapeutics-and-viacyte-inc-announce-first-patient-dosed-in-phase-1-clinical-trial-of-novel-gene-edited-cell-replacement-therapy-for-treatment-of-type-1-diabetes-t1d."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/humu.9485","article-title":"Spectrum of NPHP6\/CEP290 Mutations in Leber Congenital Amaurosis and Delineation of the Associated Phenotype","volume":"28","author":"Perrault","year":"2007","journal-title":"Hum. Mutat."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41591-018-0327-9","article-title":"Development of a Gene-Editing Approach to Restore Vision Loss in Leber Congenital Amaurosis Type 10","volume":"25","author":"Maeder","year":"2019","journal-title":"Nat. Med."},{"key":"ref_121","unstructured":"(2022, December 15). Editas Medicine. Press Release: Editas Medicine Announces Clinical Data Demonstrating Proof of Concept of EDIT-101 from Phase 1\/2 BRILLIANCE Trial. Available online: https:\/\/ir.editasmedicine.com\/news-releases\/news-release-details\/editas-medicine-announces-clinical-data-demonstrating-proof."},{"key":"ref_122","unstructured":"Longhurst, H. (2022). American College of Allergy, Asthma, and Immunology 2002 Annual Scientific Meeting, Elsevier."},{"key":"ref_123","unstructured":"(2022, December 15). Intellia Theraputics. Press Release: Intellia Therapeutics Presents New Interim Data from First-in-Human Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the American College of Allergy, Asthma & Immunology 2022 Annual Scientific Meeting. Available online: https:\/\/ir.intelliatx.com\/news-releases\/news-release-details\/intellia-therapeutics-presents-new-interim-data-first-human."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0960-8966(91)90039-U","article-title":"Population Frequencies of Inherited Neuromuscular Diseases--a World Survey","volume":"1","author":"Emery","year":"1991","journal-title":"Neuromuscul. Disord. NMD"},{"key":"ref_125","unstructured":"(2022, December 15). US National Library of Medicine, ClinicalTrials.gov, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT05144386."},{"key":"ref_126","unstructured":"(2022, December 15). US National Library of Medicine, ClinicalTrials.gov, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT05143307."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"6065","DOI":"10.1038\/s41467-020-19821-7","article-title":"CRISPR Based Editing of SIV Proviral DNA in ART Treated Non-Human Primates","volume":"11","author":"Mancuso","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_128","unstructured":"(2022, September 15). Excision BioTheraputics. Press Release: Excision BioTherapeutics Doses First Participant in EBT-101 Phase 1\/2 Trial Evaluating EBT-101 as a Potential Cure for HIV, 2022. [Press Release]. Available online: https:\/\/www.globenewswire.com\/news-release\/2022\/09\/15\/2516733\/0\/en\/Excision-BioTherapeutics-Doses-First-Participant-in-EBT-101-Phase-1-2-Trial-Evaluating-EBT-101-as-a-Potential-Cure-for-HIV.html."},{"key":"ref_129","unstructured":"(2022, December 15). US National Library of Medicine, ClinicalTrials.gov, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT03164135."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3109\/10606820212135","article-title":"CCR5 and HIV Infection","volume":"8","author":"Blanpain","year":"2002","journal-title":"Recept. Channels"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1056\/NEJMoa1817426","article-title":"CRISPR-Edited Stem Cells in a Patient with HIV and Acute Lymphocytic Leukemia","volume":"381","author":"Xu","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_132","unstructured":"(2022, December 15). US National Library of Medicine, ClinicalTrials.gov, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT03057912."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.omto.2021.12.011","article-title":"Gene Knock-out Chain Reaction Enables High Disruption Efficiency of HPV18 E6\/E7 Genes in Cervical Cancer Cells","volume":"24","author":"Tian","year":"2022","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"104794","DOI":"10.1016\/j.antiviral.2020.104794","article-title":"In Vitro and in Vivo Growth Inhibition of Human Cervical Cancer Cells via Human Papillomavirus E6\/E7 MRNAs\u2019 Cleavage by CRISPR\/Cas13a System","volume":"178","author":"Chen","year":"2020","journal-title":"Antivir. Res."},{"key":"ref_135","unstructured":"(2022, December 15). US National Library of Medicine, ClinicalTrials.gov, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT04560790."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41587-020-00781-8","article-title":"Targeting Herpes Simplex Virus with CRISPR-Cas9 Cures Herpetic Stromal Keratitis in Mice","volume":"39","author":"Yin","year":"2021","journal-title":"Nat. Biotechnol."},{"key":"ref_137","unstructured":"(2022, June 24). BDGene Theraputics. BD111 of BDgene Passed the FDA Orphan Drug Application. [151 Press Release]. Available online: https:\/\/www.bdgenetherapeutics.com\/en\/news\/77.html."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/nature17946","article-title":"Programmable Editing of a Target Base in Genomic DNA without Double-Stranded DNA Cleavage","volume":"533","author":"Komor","year":"2016","journal-title":"Nature"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"aaf8729","DOI":"10.1126\/science.aaf8729","article-title":"Targeted Nucleotide Editing Using Hybrid Prokaryotic and Vertebrate Adaptive Immune Systems","volume":"353","author":"Nishida","year":"2016","journal-title":"Science"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nature24644","article-title":"Programmable Base Editing of A\u2022T to G\u2022C in Genomic DNA without DNA Cleavage","volume":"551","author":"Gaudelli","year":"2017","journal-title":"Nature"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","article-title":"Search-and-Replace Genome Editing without Double-Strand Breaks or Donor DNA","volume":"576","author":"Anzalone","year":"2019","journal-title":"Nature"},{"key":"ref_142","unstructured":"(2022, December 15). US National Library of Medicine, ClinicalTrials.gov, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT05398029."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial Hypercholesterolaemia Is Underdiagnosed and Undertreated in the General Population: Guidance for Clinicians to Prevent Coronary Heart Disease: Consensus Statement of the European Atherosclerosis Society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur. Heart J."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 Cause Autosomal Dominant Hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat. Genet."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"e002162","DOI":"10.1161\/CIRCGEN.118.002162","article-title":"Large-Scale Phenome-Wide Association Study of PCSK9 Variants Demonstrates Protection Against Ischemic Stroke","volume":"11","author":"Rao","year":"2018","journal-title":"Circ. Genom. Precis. Med."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","article-title":"Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia","volume":"382","author":"Raal","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/s41586-021-03534-y","article-title":"In Vivo CRISPR Base Editing of PCSK9 Durably Lowers Cholesterol in Primates","volume":"593","author":"Musunuru","year":"2021","journal-title":"Nature"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1161\/CIRCULATIONAHA.122.062132","article-title":"Efficacy and Safety of an Investigational Single-Course CRISPR Base Editing Therapy Targeting PCSK9 in Non-Human Primate and Mouse Models","volume":"147","author":"Lee","year":"2022","journal-title":"Circulation"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/s41587-021-00933-4","article-title":"In Vivo Adenine Base Editing of PCSK9 in Macaques Reduces LDL Cholesterol Levels","volume":"39","author":"Rothgangl","year":"2021","journal-title":"Nat. Biotechnol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1182\/blood-2022-169114","article-title":"Tvt CAR7: Phase 1 Clinical Trial of Base-Edited \u201cUniversal\u201d CAR7 T Cells for Paediatric Relapsed\/Refractory T-ALL","volume":"140","author":"Chiesa","year":"2022","journal-title":"Blood."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1038\/s41375-021-01282-6","article-title":"Base-Edited CAR T Cells for Combinational Therapy against T Cell Malignancies","volume":"35","author":"Georgiadis","year":"2021","journal-title":"Leukemia"},{"key":"ref_153","unstructured":"(2022, December 21). UCL. World-First Use of Base-Edited CAR T-Cells to Treat Resistant Leukaemia; UCL Great Ormond Street Institute of Child Health. Available online: https:\/\/www.ucl.ac.uk\/child-health\/news\/2022\/dec\/world-first-use-base-edited-car-t-cells-treat-resistant-leukaemia."},{"key":"ref_154","unstructured":"Bain, B.J., Bates, I., and Laffan, M.A. (2017). Dacie and Lewis Practical Haematology, Elsevier. [12th ed.]."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1016\/j.drudis.2021.04.003","article-title":"Immunotherapy to Get on Point with Base Editing","volume":"26","author":"Harbottle","year":"2021","journal-title":"Drug Discov. Today"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.cell.2013.06.044","article-title":"CRISPR-Mediated Modular RNA-Guided Regulation of Transcription in Eukaryotes","volume":"154","author":"Gilbert","year":"2013","journal-title":"Cell"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.cell.2014.09.029","article-title":"Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation","volume":"159","author":"Gilbert","year":"2014","journal-title":"Cell"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"4509","DOI":"10.1073\/pnas.91.10.4509","article-title":"3rd. Kr\u00fcppel-Associated Boxes Are Potent Transcriptional Repression Domains","volume":"91","author":"Margolin","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_159","doi-asserted-by":"crossref","unstructured":"Groner, A.C., Meylan, S., Ciuffi, A., Zangger, N., Ambrosini, G., D\u00e9nervaud, N., Bucher, P., and Trono, D. (2010). KRAB-Zinc Finger Proteins and KAP1 Can Mediate Long-Range Transcriptional Repression through Heterochromatin Spreading. PLoS Genet., 6.","DOI":"10.1371\/journal.pgen.1000869"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1038\/nmeth.2598","article-title":"CRISPR RNA-Guided Activation of Endogenous Human Genes","volume":"10","author":"Maeder","year":"2013","journal-title":"Nat. Methods"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/nature14136","article-title":"Genome-Scale Transcriptional Activation by an Engineered CRISPR-Cas9 Complex","volume":"517","author":"Konermann","year":"2015","journal-title":"Nature"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/nmeth.3312","article-title":"Highly Efficient Cas9-Mediated Transcriptional Programming","volume":"12","author":"Chavez","year":"2015","journal-title":"Nat. Methods"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41556-020-00620-7","article-title":"CRISPR Technologies for Precise Epigenome Editing","volume":"23","author":"Nakamura","year":"2021","journal-title":"Nat. Cell Biol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1242\/bio.019067","article-title":"Reprogrammable CRISPR\/Cas9-Based System for Inducing Site-Specific DNA Methylation","volume":"5","author":"McDonald","year":"2016","journal-title":"Biol. Open"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.cell.2016.08.056","article-title":"Editing DNA Methylation in the Mammalian Genome","volume":"167","author":"Liu","year":"2016","journal-title":"Cell"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1093\/nar\/gkw1112","article-title":"Efficient Targeted DNA Methylation with Chimeric DCas9-Dnmt3a-Dnmt3L Methyltransferase","volume":"45","author":"Stepper","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1038\/nmeth.3630","article-title":"Highly Specific Epigenome Editing by CRISPR-Cas9 Repressors for Silencing of Distal Regulatory Elements","volume":"12","author":"Thakore","year":"2015","journal-title":"Nat. Methods"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/nbt.3199","article-title":"Epigenome Editing by a CRISPR-Cas9-Based Acetyltransferase Activates Genes from Promoters and Enhancers","volume":"33","author":"Hilton","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.cell.2016.09.006","article-title":"Inheritable Silencing of Endogenous Genes by Hit-and-Run Targeted Epigenetic Editing","volume":"167","author":"Amabile","year":"2016","journal-title":"Cell"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41434-021-00258-6","article-title":"Restoration of RPGR Expression in Vivo Using CRISPR\/Cas9 Gene Editing","volume":"29","author":"Gumerson","year":"2022","journal-title":"Gene Ther."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1016\/j.ymthe.2018.04.017","article-title":"In Situ Gene Therapy via AAV-CRISPR-Cas9-Mediated Targeted Gene Regulation","volume":"26","author":"Moreno","year":"2018","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0042-6989(01)00146-8","article-title":"Retinal Degeneration Mutants in the Mouse","volume":"42","author":"Chang","year":"2002","journal-title":"Vision Res."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"14716","DOI":"10.1038\/ncomms14716","article-title":"Nrl Knockdown by AAV-Delivered CRISPR\/Cas9 Prevents Retinal Degeneration in Mice","volume":"8","author":"Yu","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/cr.2017.57","article-title":"Gene and Mutation Independent Therapy via CRISPR-Cas9 Mediated Cellular Reprogramming in Rod Photoreceptors","volume":"27","author":"Zhu","year":"2017","journal-title":"Cell Res."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/ng0297-216","article-title":"Retinopathy Induced in Mice by Targeted Disruption of the Rhodopsin Gene","volume":"15","author":"Humphries","year":"1997","journal-title":"Nat. Genet."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.preteyeres.2017.10.002","article-title":"The Molecular and Cellular Basis of Rhodopsin Retinitis Pigmentosa Reveals Potential Strategies for Therapy","volume":"62","author":"Athanasiou","year":"2018","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1016\/S0140-6736(06)69740-7","article-title":"Retinitis Pigmentosa","volume":"368","author":"Hartong","year":"2006","journal-title":"Lancet"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1098\/rstb.2009.0077","article-title":"Evolution of Vertebrate Rod and Cone Phototransduction Genes","volume":"364","author":"Larhammar","year":"2009","journal-title":"Philos. Trans. R. Soc. Lond. B. Biol. Sci."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1212\/WNL.0000000000000797","article-title":"Population-Based Incidence and Prevalence of Facioscapulohumeral Dystrophy","volume":"83","author":"Deenen","year":"2014","journal-title":"Neurology"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1093\/hmg\/2.12.2037","article-title":"FSHD Associated DNA Rearrangements Are Due to Deletions of Integral Copies of a 3.2 Kb Tandemly Repeated Unit","volume":"2","author":"Wijmenga","year":"1993","journal-title":"Hum. Mol. Genet."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/ng0992-26","article-title":"Chromosome 4q DNA Rearrangements Associated with Facioscapulohumeral Muscular Dystrophy","volume":"2","author":"Wijmenga","year":"1992","journal-title":"Nat. Genet."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/mt.2015.200","article-title":"CRISPR\/DCas9-Mediated Transcriptional Inhibition Ameliorates the Epigenetic Dysregulation at D4Z4 and Represses DUX4-Fl in FSH Muscular Dystrophy","volume":"24","author":"Himeda","year":"2016","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3389\/fendo.2018.00338","article-title":"PTEN: Tumor Suppressor and Metabolic Regulator","volume":"9","author":"Chen","year":"2018","journal-title":"Front. Endocrinol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1158\/2159-8290.CD-12-0221","article-title":"Mechanisms of BRCA1 Tumor Suppression","volume":"2","author":"Silver","year":"2012","journal-title":"Cancer Discov."},{"key":"ref_185","first-page":"5","article-title":"The CDKN2A (P16) Gene and Human Cancer","volume":"3","author":"Foulkes","year":"1997","journal-title":"Mol. Med. Camb. Mass"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1155\/2007\/291538","article-title":"The Role of RASSF1A Methylation in Cancer","volume":"23","author":"Hesson","year":"2007","journal-title":"Dis. Markers"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1016\/j.celrep.2018.01.070","article-title":"Transcriptional Repressor HIC1 Contributes to Suppressive Function of Human Induced Regulatory T Cells","volume":"22","author":"Ullah","year":"2018","journal-title":"Cell Rep."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s12032-017-1054-7","article-title":"Progranulin and Its Biological Effects in Cancer","volume":"34","author":"Gerton","year":"2017","journal-title":"Med. Oncol."},{"key":"ref_189","first-page":"55","article-title":"The Biological Relevance of FHL2 in Tumour Cells and Its Role as a Putative Cancer Target","volume":"27","author":"Kleiber","year":"2007","journal-title":"Anticancer Res."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"13259","DOI":"10.1073\/pnas.96.23.13259","article-title":"Functional Analysis of CNK in RAS Signaling","volume":"96","author":"Therrien","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/1098-1004(200008)16:2<109::AID-HUMU3>3.0.CO;2-0","article-title":"Mutations of the Human PTEN Gene","volume":"16","author":"Bonneau","year":"2000","journal-title":"Hum. Mutat."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1016\/j.biochi.2012.07.025","article-title":"DNA Methylation Inhibitors in Cancer: Recent and Future Approaches","volume":"94","author":"Gros","year":"2012","journal-title":"Biochimie"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"3014","DOI":"10.1158\/0008-5472.CAN-2401-2","article-title":"Frequent Inactivation of PTEN by Promoter Hypermethylation in Microsatellite Instability-High Sporadic Colorectal Cancers","volume":"64","author":"Goel","year":"2004","journal-title":"Cancer Res."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/labinvest.3780422","article-title":"Promoter Methylation and Silencing of PTEN in Gastric Carcinoma","volume":"82","author":"Kang","year":"2002","journal-title":"Lab. Investig. J. Tech. Methods Pathol."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/gcc.20062","article-title":"Promoter Methylation of the PTEN Gene Is a Common Molecular Change in Breast Cancer","volume":"41","author":"Silva","year":"2004","journal-title":"Genes. Chromosomes Cancer"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/1097-0215(20010101)91:1<22::AID-IJC1002>3.0.CO;2-S","article-title":"PTEN Methylation Is Associated with Advanced Stage and Microsatellite Instability in Endometrial Carcinoma","volume":"91","author":"Salvesen","year":"2001","journal-title":"Int. J. Cancer"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.omtn.2018.12.003","article-title":"Activating PTEN Tumor Suppressor Expression with the CRISPR\/DCas9 System","volume":"14","author":"Moses","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1038\/s41467-017-01078-2","article-title":"Hit-and-Run Epigenetic Editing Prevents Senescence Entry in Primary Breast Cells from Healthy Donors","volume":"8","author":"Saunderson","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/sj.onc.1201919","article-title":"Increased P16 Expression with First Senescence Arrest in Human Mammary Epithelial Cells and Extended Growth Capacity with P16 Inactivation","volume":"17","author":"Brenner","year":"1998","journal-title":"Oncogene"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41431-018-0267-3","article-title":"A Genome-Wide Search for New Imprinted Genes in the Human Placenta Identifies DSCAM as the First Imprinted Gene on Chromosome 21","volume":"27","author":"Backer","year":"2019","journal-title":"Eur. J. Hum. Genet. EJHG"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s13148-015-0143-8","article-title":"Imprinting Disorders: A Group of Congenital Disorders with Overlapping Patterns of Molecular Changes Affecting Imprinted Loci","volume":"7","author":"Eggermann","year":"2015","journal-title":"Clin. Epigenetics"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1146\/annurev-genet-110410-132459","article-title":"Genomic Imprinting: A Mammalian Epigenetic Discovery Model","volume":"45","author":"Barlow","year":"2011","journal-title":"Annu. Rev. Genet."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.tins.2011.04.001","article-title":"Angelman Syndrome: Insights into Genomic Imprinting and Neurodevelopmental Phenotypes","volume":"34","author":"Mabb","year":"2011","journal-title":"Trends Neurosci."},{"key":"ref_204","unstructured":"Adam, M.P., Everman, D.B., Mirzaa, G.M., Pagon, R.A., Wallace, S.E., Bean, L.J., Gripp, K.W., and Amemiya, A. (1993). GeneReviews\u00ae, University of Washington, Seattle."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/s41586-020-2835-2","article-title":"Cas9 Gene Therapy for Angelman Syndrome Traps Ube3a-ATS Long Non-Coding RNA","volume":"587","author":"Wolter","year":"2020","journal-title":"Nature"},{"key":"ref_206","doi-asserted-by":"crossref","unstructured":"Syding, L.A., Nickl, P., Kasparek, P., and Sedlacek, R. (2020). CRISPR\/Cas9 Epigenome Editing Potential for Rare Imprinting Diseases: A Review. Cells, 9.","DOI":"10.3390\/cells9040993"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"a007096","DOI":"10.1101\/cshperspect.a007096","article-title":"HIV Latency","volume":"1","author":"Siliciano","year":"2011","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12977-022-00600-9","article-title":"Repression of HIV-1 Reactivation Mediated by CRISPR\/DCas9-KRAB in Lymphoid and Myeloid Cell Models","volume":"19","author":"Bomfim","year":"2022","journal-title":"Retrovirology"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/nbt.2889","article-title":"Genome-Wide Binding of the CRISPR Endonuclease Cas9 in Mammalian Cells","volume":"32","author":"Wu","year":"2014","journal-title":"Nat. Biotechnol."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nbt.2916","article-title":"Genome-Wide Analysis Reveals Characteristics of off-Target Sites Bound by the Cas9 Endonuclease","volume":"32","author":"Kuscu","year":"2014","journal-title":"Nat. Biotechnol."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/nature13589","article-title":"CRISPR-Mediated Direct Mutation of Cancer Genes in the Mouse Liver","volume":"514","author":"Xue","year":"2014","journal-title":"Nature"},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ymeth.2020.04.006","article-title":"Targeting Cancer Epigenetics with CRISPR-DCAS9: Principles and Prospects","volume":"187","author":"Rahman","year":"2021","journal-title":"Methods San Diego Calif."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00335-017-9697-4","article-title":"CRISPR-Cas Orthologues and Variants: Optimizing the Repertoire, Specificity and Delivery of Genome Engineering Tools","volume":"28","author":"Davies","year":"2017","journal-title":"Mamm. Genome Off. J. Int. Mamm. Genome Soc."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/mt.2009.255","article-title":"Effect of Genome Size on AAV Vector Packaging","volume":"18","author":"Wu","year":"2010","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.omtm.2019.01.008","article-title":"Capsid Modifications for Targeting and Improving the Efficacy of AAV Vectors","volume":"12","author":"Srivastava","year":"2019","journal-title":"Mol. Ther.-Methods Clin. Dev."},{"key":"ref_216","doi-asserted-by":"crossref","unstructured":"Gutierrez-Guerrero, A., Cosset, F.-L., and Verhoeyen, E. (2020). Lentiviral Vector Pseudotypes: Precious Tools to Improve Gene Modification of Hematopoietic Cells for Research and Gene Therapy. Viruses, 12.","DOI":"10.3390\/v12091016"},{"key":"ref_217","doi-asserted-by":"crossref","unstructured":"Yip, B.H. (2020). Recent Advances in CRISPR\/Cas9 Delivery Strategies. Biomolecules, 10.","DOI":"10.3390\/biom10060839"},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1080\/10717544.2018.1474964","article-title":"Delivering CRISPR: A Review of the Challenges and Approaches","volume":"25","author":"Lino","year":"2018","journal-title":"Drug Deliv."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41392-021-00487-6","article-title":"Viral Vector Platforms within the Gene Therapy Landscape","volume":"6","author":"Bulcha","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/s41568-022-00441-w","article-title":"CRISPR in Cancer Biology and Therapy","volume":"22","author":"Katti","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1038\/s41467-018-05067-x","article-title":"Human Pluripotent Reprogramming with CRISPR Activators","volume":"9","author":"Weltner","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1016\/j.cell.2021.03.025","article-title":"Genome-Wide Programmable Transcriptional Memory by CRISPR-Based Epigenome Editing","volume":"184","author":"Chen","year":"2021","journal-title":"Cell"},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"4354","DOI":"10.1016\/j.molcel.2021.10.014","article-title":"New Type III CRISPR Variant and Programmable RNA Targeting Tool: Oh, Thank Heaven for Cas7-11","volume":"81","author":"Catchpole","year":"2021","journal-title":"Mol. Cell"},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/0092-8674(88)90253-X","article-title":"An Unwinding Activity That Covalently Modifies Its Double-Stranded RNA Substrate","volume":"55","author":"Bass","year":"1988","journal-title":"Cell"},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1093\/nar\/19.13.3569","article-title":"Characterization of the Apolipoprotein B MRNA Editing Enzyme: No Similarity to the Proposed Mechanism of RNA Editing in Kinetoplastid Protozoa","volume":"19","author":"Greeve","year":"1991","journal-title":"Nucleic Acids Res."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1186\/gb-2012-13-12-252","article-title":"The ADAR Protein Family","volume":"13","author":"Savva","year":"2012","journal-title":"Genome Biol."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/wsbm.10","article-title":"Adenosine-to-Inosine RNA Editing","volume":"1","author":"Zinshteyn","year":"2009","journal-title":"WIREs Syst. Biol. Med."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.tibs.2016.05.001","article-title":"The APOBEC Protein Family: United by Structure, Divergent in Function","volume":"41","author":"Salter","year":"2016","journal-title":"Trends Biochem. Sci."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"8298","DOI":"10.1073\/pnas.92.18.8298","article-title":"Toward the Therapeutic Editing of Mutated RNA Sequences","volume":"92","author":"Woolf","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s43141-020-00078-y","article-title":"The Genome Editing Revolution: Review","volume":"18","author":"Khalil","year":"2020","journal-title":"J. Genet. Eng. Biotechnol."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"628137","DOI":"10.3389\/fbioe.2021.628137","article-title":"The Limitless Future of RNA Therapeutics","volume":"9","author":"Damase","year":"2021","journal-title":"Front. Bioeng. Biotechnol."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.molcel.2015.10.008","article-title":"Discovery and Functional Characterization of Diverse Class 2 CRISPR-Cas Systems","volume":"60","author":"Shmakov","year":"2015","journal-title":"Mol. Cell"},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"aaf5573","DOI":"10.1126\/science.aaf5573","article-title":"C2c2 Is a Single-Component Programmable RNA-Guided RNA-Targeting CRISPR Effector","volume":"353","author":"Abudayyeh","year":"2016","journal-title":"Science"},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1021\/acssynbio.1c00107","article-title":"CRISPR-Cas13 System as a Promising and Versatile Tool for Cancer Diagnosis, Therapy, and Research","volume":"10","author":"Palaz","year":"2021","journal-title":"ACS Synth. Biol."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1126\/science.aax7063","article-title":"A Cytosine Deaminase for Programmable Single-Base RNA Editing","volume":"365","author":"Abudayyeh","year":"2019","journal-title":"Science"},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"102789","DOI":"10.1016\/j.copbio.2022.102789","article-title":"The Double Life of CRISPR\u2013Cas13","volume":"78","author":"Bot","year":"2022","journal-title":"Curr. Opin. Biotechnol."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1126\/science.abk2718","article-title":"The GRAMP CRISPR-Cas Effector Is an RNA Endonuclease Complexed with a Caspase-like Peptidase","volume":"373","author":"Haagsma","year":"2021","journal-title":"Science"},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1016\/j.cell.2022.05.003","article-title":"Structure and Engineering of the Type III-E CRISPR-Cas7-11 Effector Complex","volume":"185","author":"Kato","year":"2022","journal-title":"Cell"},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"703860","DOI":"10.3389\/fgene.2021.703860","article-title":"Non-Coding RNA Networks in Pulmonary Hypertension","volume":"12","author":"Zang","year":"2021","journal-title":"Front. Genet."},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"NS20190099","DOI":"10.1042\/NS20190099","article-title":"Non-Coding RNAs in Neuropathic Pain","volume":"4","author":"Kalpachidou","year":"2020","journal-title":"Neuronal Signal."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1677\/JME-07-0160","article-title":"RNAs as Extracellular Signaling Molecules","volume":"40","author":"Dinger","year":"2008","journal-title":"J. Mol. Endocrinol."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"919155","DOI":"10.3389\/fcell.2022.919155","article-title":"Application of CRISPR\/Cas9 System in Establishing Large Animal Models","volume":"10","author":"Lin","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1093\/nsr\/nwz013","article-title":"Genome Editing in Large Animals: Current Status and Future Prospects","volume":"6","author":"Zhao","year":"2019","journal-title":"Natl. Sci. Rev."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/s41419-019-2056-5","article-title":"Preparation of a New Type 2 Diabetic Miniature Pig Model via the CRISPR\/Cas9 System","volume":"10","author":"Zou","year":"2019","journal-title":"Cell Death Dis."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.cell.2014.01.027","article-title":"Generation of Gene-Modified Cynomolgus Monkey via Cas9\/RNA-Mediated Gene Targeting in One-Cell Embryos","volume":"156","author":"Niu","year":"2014","journal-title":"Cell"},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/cr.2014.167","article-title":"Germline Acquisition of Cas9\/RNA-Mediated Gene Modifications in Monkeys","volume":"25","author":"Chen","year":"2015","journal-title":"Cell Res."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"3764","DOI":"10.1093\/hmg\/ddv120","article-title":"Functional Disruption of the Dystrophin Gene in Rhesus Monkey Using CRISPR\/Cas9","volume":"24","author":"Chen","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13024-019-0321-9","article-title":"A CRISPR Monkey Model Unravels a Unique Function of PINK1 in Primate Brains","volume":"14","author":"Yang","year":"2019","journal-title":"Mol. Neurodegener."},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/s41422-019-0142-y","article-title":"CRISPR\/Cas9-Mediated PINK1 Deletion Leads to Neurodegeneration in Rhesus Monkeys","volume":"29","author":"Yang","year":"2019","journal-title":"Cell Res."},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1007\/s12264-021-00732-6","article-title":"Co-Editing PINK1 and DJ-1 Genes Via Adeno-Associated Virus-Delivered CRISPR\/Cas9 System in Adult Monkey Brain Elicits Classical Parkinsonian Phenotype","volume":"37","author":"Li","year":"2021","journal-title":"Neurosci. Bull."},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s13238-021-00889-w","article-title":"PINK1 Mediates Neuronal Survival in Monkey","volume":"13","author":"Sun","year":"2022","journal-title":"Protein Cell"},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s13238-021-00888-x","article-title":"PINK1 Kinase Dysfunction Triggers Neurodegeneration in the Primate Brain without Impacting Mitochondrial Homeostasis","volume":"13","author":"Yang","year":"2022","journal-title":"Protein Cell"},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"7255","DOI":"10.1093\/hmg\/ddv425","article-title":"CRISPR\/Cas9-Mediated Dax1 Knockout in the Monkey Recapitulates Human AHC-HH","volume":"24","author":"Kang","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/hmg\/ddy367","article-title":"CRISPR\/Cas9-Mediated Disruption of SHANK3 in Monkey Leads to Drug-Treatable Autism-like Symptoms","volume":"28","author":"Tu","year":"2018","journal-title":"Hum. Mol. Genet."},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1038\/cr.2017.95","article-title":"Altered Neurogenesis and Disrupted Expression of Synaptic Proteins in Prefrontal Cortex of SHANK3-Deficient Non-Human Primate","volume":"27","author":"Zhao","year":"2017","journal-title":"Cell Res."},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/cr.2014.11","article-title":"One-Step Generation of Knockout Pigs by Zygote Injection of CRISPR\/Cas System","volume":"24","author":"Hai","year":"2014","journal-title":"Cell Res."},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1095\/biolreprod.114.121723","article-title":"Use of the CRISPR\/Cas9 System to Produce Genetically Engineered Pigs from In Vitro-Derived Oocytes and Embryos1","volume":"91","author":"Whitworth","year":"2014","journal-title":"Biol. Reprod."},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s00018-014-1744-7","article-title":"Generation of CRISPR\/Cas9-Mediated Gene-Targeted Pigs via Somatic Cell Nuclear Transfer","volume":"72","author":"Zhou","year":"2015","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"20620","DOI":"10.1038\/srep20620","article-title":"One-Step Generation of Triple Gene-Targeted Pigs Using CRISPR\/Cas9 System","volume":"6","author":"Wang","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"e141523","DOI":"10.1172\/jci.insight.141523","article-title":"A Porcine Model of Phenylketonuria Generated by CRISPR\/Cas9 Genome Editing","volume":"5","author":"Koppes","year":"2020","journal-title":"JCI Insight"},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.cell.2018.03.005","article-title":"A Huntingtin Knockin Pig Model Recapitulates Features of Selective Neurodegeneration in Huntington\u2019s Disease","volume":"173","author":"Yan","year":"2018","journal-title":"Cell"},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s42003-018-0163-y","article-title":"Genetically Engineered Minipigs Model the Major Clinical Features of Human Neurofibromatosis Type 1","volume":"1","author":"Isakson","year":"2018","journal-title":"Commun. Biol."},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"115450","DOI":"10.1016\/j.bone.2020.115450","article-title":"A CRISPR-Engineered Swine Model of COL2A1 Deficiency Recapitulates Altered Early Skeletal Developmental Defects in Humans","volume":"137","author":"Zhang","year":"2020","journal-title":"Bone"},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1262\/jrd.2016-079","article-title":"Production of A1,3-Galactosyltransferase and Cytidine Monophosphate-N-Acetylneuraminic Acid Hydroxylase Gene Double-Deficient Pigs by CRISPR\/Cas9 and Handmade Cloning","volume":"63","author":"Gao","year":"2017","journal-title":"J. Reprod. Dev."},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1080\/10495398.2016.1246453","article-title":"Generation of GGTA1 Mutant Pigs by Direct Pronuclear Microinjection of CRISPR\/Cas9 Plasmid Vectors","volume":"28","author":"Chuang","year":"2017","journal-title":"Anim. Biotechnol."},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s13205-018-1107-4","article-title":"The Production of UL16-Binding Protein 1 Targeted Pigs Using CRISPR Technology","volume":"8","author":"Joanna","year":"2018","journal-title":"3 Biotech"},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1126\/science.aad1191","article-title":"Genome-Wide Inactivation of Porcine Endogenous Retroviruses (PERVs)","volume":"350","author":"Yang","year":"2015","journal-title":"Science"},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s41551-020-00613-9","article-title":"Extensive Germline Genome Engineering in Pigs","volume":"5","author":"Yue","year":"2021","journal-title":"Nat. Biomed. Eng."},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1111\/ajt.16930","article-title":"First Clinical-Grade Porcine Kidney Xenotransplant Using a Human Decedent Model","volume":"22","author":"Porrett","year":"2022","journal-title":"Am. J. Transplant."},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa2201422","article-title":"Genetically Modified Porcine-to-Human Cardiac Xenotransplantation","volume":"387","author":"Griffith","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"e123529","DOI":"10.1172\/jci.insight.123529","article-title":"A Sheep Model of Cystic Fibrosis Generated by CRISPR\/Cas9 Disruption of the CFTR Gene","volume":"3","author":"Fan","year":"2018","journal-title":"JCI Insight"},{"key":"ref_272","doi-asserted-by":"crossref","first-page":"16945","DOI":"10.1038\/s41598-018-35079-y","article-title":"Genetic Engineering a Large Animal Model of Human Hypophosphatasia in Sheep","volume":"8","author":"Williams","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_273","doi-asserted-by":"crossref","first-page":"5995","DOI":"10.1038\/s41598-020-62879-y","article-title":"Otoferlin Gene Editing in Sheep via CRISPR-Assisted SsODN-Mediated Homology Directed Repair","volume":"10","author":"Menchaca","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_274","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1126\/science.aau1549","article-title":"Gene Editing Restores Dystrophin Expression in a Canine Model of Duchenne Muscular Dystrophy","volume":"362","author":"Amoasii","year":"2018","journal-title":"Science"},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/cr.2018.10","article-title":"Generation of a Precise Oct4-HrGFP Knockin Cynomolgus Monkey Model via CRISPR\/Cas9-Assisted Homologous Recombination","volume":"28","author":"Cui","year":"2018","journal-title":"Cell Res."},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"24360","DOI":"10.1038\/srep24360","article-title":"Rosa26-Targeted Sheep Gene Knock-in via CRISPR-Cas9 System","volume":"6","author":"Wu","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_277","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ydbio.2018.10.008","article-title":"Mosaicism in CRISPR\/Cas9-Mediated Genome Editing","volume":"445","author":"Mehravar","year":"2019","journal-title":"Dev. Biol."},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"42081","DOI":"10.1038\/srep42081","article-title":"Promoting Cas9 Degradation Reduces Mosaic Mutations in Non-Human Primate Embryos","volume":"7","author":"Tu","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_279","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41421-018-0065-7","article-title":"Efficient RNA-Guided Base Editing for Disease Modeling in Pigs","volume":"4","author":"Li","year":"2018","journal-title":"Cell Discov."},{"key":"ref_280","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s13238-020-00740-8","article-title":"Generation of a Hutchinson\u2013Gilford Progeria Syndrome Monkey Model by Base Editing","volume":"11","author":"Wang","year":"2020","journal-title":"Protein Cell"},{"key":"ref_281","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1038\/s41467-019-10421-8","article-title":"Efficient Base Editing for Multiple Genes and Loci in Pigs Using Base Editors","volume":"10","author":"Xie","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_282","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s00018-019-03205-2","article-title":"Efficient Base Editing by RNA-Guided Cytidine Base Editors (CBEs) in Pigs","volume":"77","author":"Yuan","year":"2020","journal-title":"Cell. Mol. Life Sci."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/12\/8\/1103\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:12:03Z","timestamp":1760123523000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/12\/8\/1103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,7]]},"references-count":282,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["cells12081103"],"URL":"https:\/\/doi.org\/10.3390\/cells12081103","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,7]]}}}